Chairman of the Board, Independent member
Chief Executive Officer
PhD, co-founder, Executive Chairman of Gensight Biologics. In charge of investments.
Bernard Gilly has over 20 years of experience in the financial and pharmaceutical sectors, and as an entrepreneur.
He was Vice-President R&D for 5 years at Pasteur Mérieux Connaught, the vaccine company that since then has become Sanofi Pasteur. Afterwards, he became the CEO of Transgene from 1992 to 2000, heading the Company's listing and raising over 160 million €. He later joined Sofinnova Partners in Paris (2000-2005). In 2005, he founded and became the CEO of Fovea Pharmaceuticals. After Fovea was acquired by Sanofi in 2009, he became Executive Vice President of the Ophthalmology Division of Sanofi.
In 2011, he founded Pixium Vision and served as Chief Executive Officer from 2012 through 2014.
Managing partner at EVERPINE Capital, Tao Wu has been a member of the EYE TECH CARE board since December 2015.
Tao Wu has over 20 years of experience in Management, Marketing and Sales as well as in International Business Development.
A Chief Executive Officer at the Chongquing Doyen Industry Co., Ltd, he led a RMB 5 billion conglomerate including two publicly listed companies, with 10,000 employees and more than 20 holding and joint venture companies located across China. As a Chairman/Site Executive of GE Medical Systems (China) Co. Ltd., he supervised a US$400 million GE Healthcare subsidiary.
He also occupied the position of General Manager, GE Healthcare (US$40 million global Performance Monitoring business) and the position of Investment Manager (market and financial analyses on a portfolio of businesses) at Linden Life Sciences LLC / Roche Diagnostics.
Tao holds a PhD from the Mayo Clinic Graduate School and an MBA from the Northwestern University.
After over 15 year of success in the medtech industry, Dietrich Wolf joined the company in 2014 with a view to establishing HIFU (High Intensity Focused Ultrasound) as a recognized future option in glaucoma care.
He recently worked for Carl Zeiss Meditec on a disruptive new technology in oncology, winning prestigious innovation awards in both Germany and the US. Prior to Zeiss, Dietrich Wolf worked at differents business divisions of Dentsply International in the field of dental implants and high-tech ceramics.
Dietrich holds a Master and a PhD in Materials Science and Engineering from the University of Erlangen, Germany. He did executive education programs at St. Gallen Business School in Switzerland, at UNC Keenan-Flagler Business School in Chapel Hill, NC and with Harvard Business School, Boston, MA.
Bernard Chauvin is a physician specializing in ophthalmology. He headed the Laboratoires Chauvin for 27 years (until its acquisition by Bausch & Lomb), prior to joining Neurotech, a French biotechnology company where he served as Chief Executive Officer until 2004.
Since then, he has taken an active role as a director in the development of a number of pharmaceutical and biotechnology companies.
Bernard Chauvin has been a member of EYE TECH CARE’s Board of Directors since march 2013.
Mounia Chaoui is General partner at Turenne Capital in charge of venture and growth capital in Healthcare.
Prior to this, Mounia has been a Life Science investor within Ventech, Inserm Transfert Initiative and Atlas Venture. She has been on the board of Biovex (sold to Amgen for up to 1B$), Funxional Therapeutics (sold to Boehringer), Tigenix (now EUR:TIG) and Scynexis (SCYX). Besides EYE TECH CARE, Mounia sits on the board of Actogenix, Alizé Pharma, Covagen, DNA therapeutics, Eyegate, Prosonix, and Sebbin.
Mounia has a PhD in Biophysics and an Engineering degree from Ecole Centrale Paris.
Mounia has been a member of the EYE TECH CARE board since July 2014.
Bruno Montanari is General partner at Omnes Capital, in charge of venture and growth capital in Life Sciences.
Bruno Montanari began his career in 1999 working in investment banking in London at Deutsche Bank, then Merrill Lynch, before moving into venture capital, initially at CDP Capital, then at Atlas Venture. He joined Omnes Capital in 2010.Bruno currently sits on the board of directors of several companies including Novate, Poxel (Euronext Paris : POXEL), Themis, Xention and previously served on the board of arGEN-X (Euronext Brussels: ARGX), EOS imaging (Euronext Paris: EOSI).
Bruno graduated with a master’s degree in Strategic Management from the HEC business school and holds a PhD in pharmaceuticals (University Paris V).
He has been a member of EYE TECH CARE board since September 2015.